Revelation Biosciences (REVB) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.76, +5.83% vs the prior close of $0.72.
- Volume 20.60K shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
REVB jumps 5.8% to $0.76. Closed at $0.76, +5.83% vs the prior close of $0.72. Day range $0.73–$0.78, opened at $0.75.
REVB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — REVB jumps 5.8% to $0.76
- Closed at $0.76, +5.83% vs the prior close of $0.72. Day range $0.73–$0.78, opened at $0.75.
- Volume was 20.60K shares, 0.6x its 50-day average of 36.05K — lighter than usual.
- Price is -20.1% vs its 50-day average ($0.95) and -42.7% vs its 200-day average ($1.33).
- 52-week range $0.71–$5.80; today's close sits at 1% of that range, 86.9% below the 52-week high.
Oct 14, 2026 — REVB dips 1.4% to $0.72, a 52-week low
- Closed at $0.72, -1.37% vs the prior close of $0.73. Day range $0.71–$0.76, opened at $0.73.
- Volume was 22.80K shares, 0.6x its 50-day average of 36.27K.
- Price is -25.1% vs its 50-day average ($0.96) and -46.4% vs its 200-day average ($1.34).
- 52-week range $0.71–$5.80; today's close sits at 0% of that range, 87.6% below the 52-week high.
Oct 13, 2026 — REVB slides 5.8% to $0.73, a 52-week low
- Closed at $0.73, -5.81% vs the prior close of $0.77. Day range $0.73–$0.77, opened at $0.76.
- Volume was 26.80K shares, 0.7x its 50-day average of 36.34K.
- Price is -24.7% vs its 50-day average ($0.97) and -46.2% vs its 200-day average ($1.36).
- 52-week range $0.73–$5.80; today's close sits at 0% of that range, 87.4% below the 52-week high.
Oct 12, 2026 — REVB rises 2.0% to $0.77
- Closed at $0.77, +1.97% vs the prior close of $0.76. Day range $0.77–$0.80, opened at $0.80.
- Volume was 12.60K shares, 0.3x its 50-day average of 36.56K — lighter than usual.
- Price is -20.6% vs its 50-day average ($0.98) and -43.4% vs its 200-day average ($1.37).
- 52-week range $0.75–$5.96; today's close sits at 0% of that range, 87.0% below the 52-week high.
Oct 9, 2026 — REVB dips 1.8% to $0.76
- Closed at $0.76, -1.81% vs the prior close of $0.77. Day range $0.75–$0.82, opened at $0.77.
- Volume was 24.80K shares, 0.7x its 50-day average of 36.70K.
- Price is -22.4% vs its 50-day average ($0.98) and -45.1% vs its 200-day average ($1.38).
- 52-week range $0.75–$6.24; today's close sits at 0% of that range, 87.8% below the 52-week high.
Oct 8, 2026 — REVB slides 6.5% to $0.77
- Closed at $0.77, -6.52% vs the prior close of $0.83. Day range $0.77–$0.81, opened at $0.81.
- Volume was 65.00K shares, 1.8x its 50-day average of 36.34K.
- Price is -21.3% vs its 50-day average ($0.98) and -44.6% vs its 200-day average ($1.40).
- 52-week range $0.75–$6.76; today's close sits at 0% of that range, 88.6% below the 52-week high.
Oct 7, 2026 — REVB jumps 10.1% to $0.83
- Closed at $0.83, +10.11% vs the prior close of $0.75. Day range $0.75–$0.84, opened at $0.75.
- Volume was 50.90K shares, 1.4x its 50-day average of 35.36K.
- Price is -16.2% vs its 50-day average ($0.99) and -41.3% vs its 200-day average ($1.41).
- 52-week range $0.75–$6.76; today's close sits at 1% of that range, 87.8% below the 52-week high.
Oct 6, 2026 — REVB slides 3.2% to $0.75, a 52-week low
- Closed at $0.75, -3.22% vs the prior close of $0.78. Day range $0.75–$0.80, opened at $0.79.
- Volume was 34.70K shares, 1.0x its 50-day average of 34.84K.
- Price is -24.2% vs its 50-day average ($0.99) and -47.2% vs its 200-day average ($1.42).
- 52-week range $0.75–$6.76; today's close sits at 0% of that range, 88.9% below the 52-week high.
Oct 5, 2026 — REVB rises 1.7% to $0.78 on 2.7x normal volume
- Closed at $0.78, +1.70% vs the prior close of $0.76. Day range $0.76–$0.83, opened at $0.79.
- Volume was 90.60K shares, 2.7x its 50-day average of 33.66K — unusually heavy trading.
- Price is -22.2% vs its 50-day average ($1.00) and -46.0% vs its 200-day average ($1.44).
- 52-week range $0.76–$6.76; today's close sits at 0% of that range, 88.5% below the 52-week high.
Oct 2, 2026 — REVB slides 4.6% to $0.76, a 52-week low
- Closed at $0.76, -4.62% vs the prior close of $0.80. Day range $0.76–$0.81, opened at $0.81.
- Volume was 43.90K shares, 1.3x its 50-day average of 33.24K.
- Price is -23.9% vs its 50-day average ($1.00) and -47.5% vs its 200-day average ($1.46).
- 52-week range $0.76–$6.76; today's close sits at 0% of that range, 88.7% below the 52-week high.
REVB latest news & SEC filings
Every SEC filing by or about REVB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.32M (prior year -$2.44M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.87 (prior year -$28.04) (loss narrowed vs Jun 30, 2025)
Jul 13, 2026 · Form 8-A12B — 8-A12B filing
8-A12B filing
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade REVB
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.54% (largest 10.1%). That is a volatile stock.
- Liquidity: about 40.19K shares (≈$30.62K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.76 vs a range of $0.71–$5.80 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:4 on Jan 28, 2026, 1:3 on Jul 7, 2025, 1:16 on Jan 28, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 19, 2026; 8-K Aug 6, 2026; 10-Q Aug 6, 2026.
- Share count: 3.98M shares outstanding (Aug 3, 2026), +134.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
REVB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.75 | 0.78 | 0.73 | 0.76 | 20.60K |
| Oct 14, 2026 | 0.73 | 0.76 | 0.71 | 0.72 | 22.80K |
| Oct 13, 2026 | 0.76 | 0.77 | 0.73 | 0.73 | 26.80K |
| Oct 12, 2026 | 0.80 | 0.80 | 0.77 | 0.77 | 12.60K |
| Oct 9, 2026 | 0.77 | 0.82 | 0.75 | 0.76 | 24.80K |
| Oct 8, 2026 | 0.81 | 0.81 | 0.77 | 0.77 | 65.00K |
| Oct 7, 2026 | 0.75 | 0.84 | 0.75 | 0.83 | 50.90K |
| Oct 6, 2026 | 0.79 | 0.80 | 0.75 | 0.75 | 34.70K |
| Oct 5, 2026 | 0.79 | 0.83 | 0.76 | 0.78 | 90.60K |
| Oct 2, 2026 | 0.81 | 0.81 | 0.76 | 0.76 | 43.90K |
| Oct 1, 2026 | 0.82 | 0.84 | 0.79 | 0.80 | 60.80K |
| Sep 30, 2026 | 0.83 | 0.85 | 0.82 | 0.82 | 30.20K |
| Sep 29, 2026 | 0.88 | 0.88 | 0.81 | 0.81 | 53.00K |
| Sep 28, 2026 | 0.88 | 0.88 | 0.83 | 0.86 | 33.20K |
| Sep 25, 2026 | 0.89 | 0.91 | 0.85 | 0.87 | 43.40K |
| Sep 24, 2026 | 0.92 | 0.94 | 0.86 | 0.87 | 71.90K |
| Sep 23, 2026 | 0.97 | 0.98 | 0.92 | 0.93 | 58.70K |
| Sep 22, 2026 | 1.00 | 1.02 | 0.96 | 0.98 | 26.40K |
| Sep 21, 2026 | 0.97 | 1.01 | 0.93 | 0.98 | 17.60K |
| Sep 18, 2026 | 0.98 | 0.98 | 0.93 | 0.93 | 15.80K |
About Revelation Biosciences
Revelation Biosciences (REVB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1810560.
REVB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jennifer Carver | Director | Aug 18, 2026 |
| Lakhmir S Chawla | Director | Aug 18, 2026 |
| Jess Roper | Director | Aug 18, 2026 |
| James Rolke | Chief Executive Officer | Aug 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Rolke | Chief Executive Officer | Aug 18, 2026 |
| Chester Stanley Iii Zygmont | Chief Financial Officer | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
REVB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-8.91M | -23.95 | $-8.27M |
| Dec 31, 2024 | — | $-15.04M | -1,052.16 | $-18.32M |
| Dec 31, 2023 | — | $-120.25K | -8.44 | $-7.29M |
| Dec 31, 2022 | — | $-10.83M | -149.20 | $-11.22M |
| Dec 31, 2021 | — | $-11.99M | -42.50 | $-11.09M |
Latest balance sheet: total assets $12.50M, total liabilities $2.43M, cash $11.48M (as of Jun 30, 2026).
REVB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $1.12 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.02 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $1.33 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $4.04 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $9.52 |
| May 8, 2025 | 8-K Item 2.02 (results) | $37.14 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $41.52 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $157.44 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 22, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on REVB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.